(NASDAQ: TVRD) Tvardi Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 40.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 100.43%.
Tvardi Therapeutics's earnings in 2025 is -$20,894,000.On average, 10 Wall Street analysts forecast TVRD's earnings for 2025 to be -$31,812,941, with the lowest TVRD earnings forecast at -$52,933,734, and the highest TVRD earnings forecast at -$23,040,353. On average, 10 Wall Street analysts forecast TVRD's earnings for 2026 to be -$24,516,361, with the lowest TVRD earnings forecast at -$52,474,240, and the highest TVRD earnings forecast at -$13,981,753. 
In 2027, TVRD is forecast to generate -$33,257,066 in earnings, with the lowest earnings forecast at -$76,735,534 and the highest earnings forecast at -$14,966,383.